Condition: Relapsed/Refractory Multiple Myeloma · Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.
This description comes directly from the study's public registry record.
Yue Song · +86-18511021346 · songyue@sumgenbio.com
Always discuss trial participation with your own doctor first.
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| The First Affiliated Hospital Of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital) | Xi’an, Shanxi, China | Recruiting |
| The Second Affiliated Hospital Zhejiang University School Of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07454187